Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in SchizophreniaGlobeNewsWire • 03/20/23
2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 YearsThe Motley Fool • 03/17/23
Does Zai Lab Limited Unsponsored ADR (ZLAB) Have the Potential to Rally 115.25% as Wall Street Analysts Expect?Zacks Investment Research • 03/06/23
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate UpdatesGlobeNewsWire • 03/01/23
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers CongressGlobeNewsWire • 02/22/23
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPAGlobeNewsWire • 02/22/23
Zai Lab Limited (ZLAB) Presents at Citi Biotech C-Suite Fireside Chat Series Conference (Transcript)Seeking Alpha • 02/14/23
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023GlobeNewsWire • 02/09/23
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China's NMPAGlobeNewsWire • 01/30/23
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China's National Reimbursement Drug ListGlobeNewsWire • 01/18/23
Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/16/23
Novocure, Zai shares rally after lung-cancer treatment meets primary endpoint in studyMarket Watch • 01/05/23
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival EndpointGlobeNewsWire • 01/05/23